Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).

Luigi Gargiulo Luciano IbbaP MalagoliR G AngileriF BardazziNicoletta BernardiniM BurlandoC G CarreraAndrea ChiricozziP DapavoValentina DiniG FabbrociniF M GaianiMarco GalluzzoC GiofréC GuarneriF LoconsoleG MalaraL MarcelliMatteo Megna Stefano Piaserico Marina Talamonti Antonio CostanzoA Narcisi

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

Our data suggest that the efficacy of guselkumab in patients with inadequate response to ustekinumab for plaque psoriasis in "real-life" clinical practice is comparable with NAVIGATE study with higher percentages of patients achieving PASI90 and PASI100 at weeks 16, 52 and 104.

Keyphrases

clinical practice
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
coronary artery disease
atopic dermatitis
big data
patient reported outcomes
artificial intelligence
data analysis